|
Video: What is a Stock Split?
|
|
Sunshine Biopharma is a pharmaceutical company. Co.'s proprietary drug development activities are focused on the development of a small molecule called Adva-27a for the treatment of aggressive forms of cancer. Co.'s Canadian wholly owned subsidiary, Sunshine Biopharma Canada Inc. has licensing agreements with a primary pharmaceutical company for four prescription generic drugs for the treatment of breast cancer, prostate cancer and enlarged prostate. These four generic products are Anastrozole, Letrozole, Bicalutamide, and Finasteride. Co. develops Essential 9, a dietary supplement comprised of the nine amino acids which the human body cannot synthesize. According to our SBFM split history records, Sunshine Biopharma has had 1 split. | |
|
Sunshine Biopharma (SBFM) has 1 split in our SBFM split history database. The split for SBFM took place on April 17, 2024. This was a 1 for 100 reverse split, meaning for each 100 shares of SBFM owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 10 share position following the split.
When a company such as Sunshine Biopharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the SBFM split history from start to finish, an original position size of 1000 shares would have turned into 10 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Sunshine Biopharma shares, starting with a $10,000 purchase of SBFM, presented on a split-history-adjusted basis factoring in the complete SBFM split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/05/2014 |
|
End date: |
05/01/2024 |
|
Start price/share: |
$16.00 |
|
End price/share: |
$0.86 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-94.62% |
|
Average Annual Total Return: |
-25.35% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$537.83 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
04/17/2024 | 1 for 100 |
|
|